A phase II trial of brivanib in recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group Study

Gynecologic Oncology

Volumn 135, Issue 1, 2014, Pages 38-43

  Powell, Matthew A ^a   Sill, Michael W ^b   Goodfellow, Paul J ^c   Benbrook, Doris M ^d   Lankes, Heather A ^b   Leslie, Kimberly K ^e   Jeske, Yvette ^f   Mannel, Robert S ^d   Spillman, Monique A ^g   Lee, Paula S ^h   Hoffman, James S ⁱ   McMeekin, D Scott ^d   Pollock, Pamela M ^f  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^e UNIVERSITY OF IOWA HOSPITALS AND CLINICS   (United States)

^f QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

^g UNIVERSITY OF COLORADO   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

ⁱ NEW BRITAIN GENERAL HOSPITAL   (United States)

Author keywords

Brivanib; Endometrial cancer

Indexed keywords

ANGIOGENIC PROTEIN; BRIVANIB; ESTROGEN RECEPTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 2; ALANINE; FGFR2 PROTEIN, HUMAN; TRIAZINE DERIVATIVE; VASCULOTROPIN A;

ADULT; AGED; ALLERGY; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLEEDING; BLOOD CLOTTING DISORDER; CANCER RECURRENCE; CLINICAL ARTICLE; CONFUSION; DIGESTIVE SYSTEM PERFORATION; DRUG DOSE REDUCTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; ENDOMETRIUM CANCER; EYE DISEASE; FEMALE; GASTROINTESTINAL SYMPTOM; HEPATOBILIARY DISEASE; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; INFECTION; LEUKOPENIA; LYMPHATIC SYSTEM DISEASE; METABOLIC DISORDER; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL DISEASE; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PAIN; PHASE 2 CLINICAL TRIAL; POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RECTUM FISTULA; SKIN DISEASE; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT RESPONSE; VASCULAR DISEASE; VERY ELDERLY; VOMITING; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; DISEASE FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; METABOLISM; MIDDLE AGED; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ALANINE; DISEASE-FREE SURVIVAL; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 2; TRIAZINES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84908030997     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.07.083     Document Type: Article

References (40)

1. J.D. Wright, J. Fiorelli, P.B. Schiff, W.M. Burke, A.L. Kansler, and C.J. Cohen Racial disparities for uterine corpus tumors: changes in clinical characteristics and treatment over time Cancer 115 2009 1276 1285
2. R. Siegel, J. Ma, Z. Zou, and A. Jemal Cancer statistics CA Cancer J Clin 64 2014 9 29
3. D.S. Miller Randomized phase III trial of doxorubicin/cisplatin/paclitaxel and G-CSF versus carboplatin/paclitaxel in patients with stage III and IV or recurrent endometrial cancer. Abstracts of the 43rd Annual Meeting of the Society of Gynecologic Oncology. March 24-27, 2012. Austin, Texas, USA Gynecol Oncol 125 Suppl. 1 2012 S2 S188
4. J.V. Fiorica, V.L. Brunetto, P. Hanjani, S.S. Lentz, R. Mannel, and W. Andersen Phase II trial of alternating courses of megestrol acetate and tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 2004 10 14
5. C.W. Whitney, V.L. Brunetto, R.J. Zaino, S.S. Lentz, J. Sorosky, and D.K. Armstrong Phase II study of medroxyprogesterone acetate plus tamoxifen in advanced endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 92 2004 4 9
6. R. Correa, H. Mackay, and H. Hirte A phase II study of sunitinib in recurrent or metastatic endometrial carcinoma: a trial of the Princess Margaret Hospital, The University of Chicago, and California Cancer Phase II Consortia J Clin Oncol 28 2010 399s (Suppl.)
7. H.S. Nimeiri, A.M. Oza, R.J. Morgan, D. Huo, L. Elit, and J.A. Knost A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia Gynecol Oncol 117 2010 37 40
8. D.S. McMeekin, M.W. Sill, D. Benbrook, K.M. Darcy, D.J. Stearns-Kurosawa, and L. Eaton A phase II trial of thalidomide in patients with refractory endometrial cancer and correlation with angiogenesis biomarkers: a Gynecologic Oncology Group study Gynecol Oncol 105 2007 508 516
9. A.M. Oza, E.A. Eisenhauer, L. Elit, J.C. Cutz, A. Sakurada, and M.S. Tsao Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148 J Clin Oncol 26 2008 4319 4325
10. L. Albitar, M.B. Carter, S. Davies, and K.K. Leslie Consequences of the loss of p53, RB1, and PTEN: relationship to gefitinib resistance in endometrial cancer Gynecol Oncol 106 2007 94 104
11. K.K. Leslie, M.W. Sill, E. Fischer, K.M. Darcy, R.S. Mannel, and K.S. Tewari A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study Gynecol Oncol 129 2013 486 494
12. C. Slomovitz, D. Miller, and K. Lu Phase II study of cetuximab (Erbitux) in patients with progressive or recurrent endometrial cancer Gynecol Oncol 116 2010 S1 S198
13. G.F. Fleming, M.W. Sill, K.M. Darcy, D.S. McMeekin, J.T. Thigpen, and L.M. Adler Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study Gynecol Oncol 116 2010 15 20
14. A.M. Oza, L. Elit, M.S. Tsao, S. Kamel-Reid, J. Biagi, and D.M. Provencher Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group J Clin Oncol 29 2011 3278 3285
15. B.M. Slomovitz, K.H. Lu, T. Johnston, R.L. Coleman, M. Munsell, and R.R. Broaddus A phase 2 study of the oral mammalian target of rapamycin inhibitor, everolimus, in patients with recurrent endometrial carcinoma Cancer 116 2010 5415 5419
16. N. Colombo, D.S. McMeekin, P.E. Schwartz, C. Sessa, P.A. Gehrig, and R. Holloway Ridaforolimus as a single agent in advanced endometrial cancer: results of a single-arm, phase 2 trial Br J Cancer 108 2013 1021 1026
17. C. Aghajanian, M.W. Sill, K.M. Darcy, B. Greer, D.S. McMeekin, and P.G. Rose Phase II trial of bevacizumab in recurrent or persistent endometrial cancer: a Gynecologic Oncology Group study J Clin Oncol 29 2011 2259 2265
18. D.M. Ornitz, and N. Itoh Fibroblast growth factors Genome Biol 2 2001 (REVIEWS3005)
19. N. Turner, and R. Grose Fibroblast growth factor signalling: from development to cancer Nat Rev Cancer 10 2010 116 129
20. P.M. Pollock, M.G. Gartside, and L.C. Dejeza Frequent activating FGFR2 mutations in endometrial carcinomas parallel germline mutations associated with craniosynostosis and skeletal dysplasia syndromes Oncogene 26 2007 7158 7162
21. S.A. Byron, M. Gartside, M.A. Powell, C.L. Wellens, F. Gao, and D.G. Mutch FGFR2 point mutations in 466 endometrioid endometrial tumors: relationship with MSI, KRAS, PIK3CA, CTNNB1 mutations and clinicopathological features PLoS One 7 2012 e30801
22. A. Dutt, H.B. Salvesen, T.H. Chen, A.H. Ramos, R.C. Onofrio, and C. Hatton Drug-sensitive FGFR2 mutations in endometrial carcinoma Proc Natl Acad Sci U S A 105 2008 8713 8717
23. S. Gatius, A. Velasco, A. Azueta, M. Santacana, J. Pallares, and J. Valls FGFR2 alterations in endometrial carcinoma Mod Pathol 24 2011 1500 1510
24. M.W. Sill, L. Rubinstein, S. Litwin, and G. Yothers A method for utilizing co-primary efficacy outcome measures to screen regimens for activity in two-stage Phase II clinical trials Clin Trials 9 4 2012 Aug 385 395 10.1177/1740774512450101 Epub 2012 Jul 18. PMID:22811448
25. C. Krakstad, E. Birkeland, D. Seidel, K. Kusonmano, K. Petersen, and S. Mios High-throughput mutation profiling of primary and metastatic endometrial cancers identifies KRAS, FGFR2 and PIK3CA to be frequently mutated PLoS One 7 2012 e52795
26. C. Beadling, M.C. Heinrich, A. Warrick, E.M. Forbes, D. Nelson, and E. Justusson Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry J Mol Diagn 13 2011 504 513
27. S.A. Byron, M.G. Gartside, C.L. Wellens, M.A. Mallon, J.B. Keenan, and M.A. Powell Inhibition of activated fibroblast growth factor receptor 2 in endometrial cancer cells induces cell death despite PTEN abrogation Cancer Res 68 2008 6902 6907
28. J.M. Gozgit, M.J. Wong, L. Moran, S. Wardwell, Q.K. Mohemmad, and N.I. Narasimhan Ponatinib (AP24534), a multitargeted pan-FGFR inhibitor with activity in multiple FGFR-amplified or mutated cancer models Mol Cancer Ther 11 2012 690 699
29. V. Guagnano, A. Kauffmann, S. Wohrle, S. Wohrle, C. Stamm, and M. Ito FGFR genetic alterations predict for sensitivity to NVP-BGJ398, a selective pan-FGFR inhibitor Cancer Discov 2 2012 1118 1133
30. P.R. Gavine, L. Mooney, and E. Kilgour AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family Cancer Res 72 2012 2045 2056
31. R.S. Finn, Y.K. Kang, M. Mulcahy, B.N. Polite, H.Y. Lim, and I. Walters Phase II, open-label study of brivanib as second-line therapy in patients with advanced hepatocellular carcinoma Clin Cancer Res 18 2012 2090 2098
32. J.W. Park, R.S. Finn, J.S. Kim, M. Karwal, R.K. Li, and F. Ismail Phase II, open-label study of brivanib as first-line therapy in patients with advanced hepatocellular carcinoma Clin Cancer Res 17 2011 1973 1983
33. P. Therasse, S.G. Arbuck, E.A. Eisenhauer, J. Wanders, R.S. Kaplan, and L. Rubinstein New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada J Natl Cancer Inst 92 2000 205 216
34. C.R. Mehta, and N.R. Patel A network algorithm for performing Fisher exact test in R × C contingency-tables J Am Stat Assoc 78 1983 427 434
35. A. Gerger, M. LaBonte, and H.J. Lenz Molecular predictors of response to antiangiogenesis therapies Cancer J 17 2011 134 141
36. S. Tsutsui, H. Inoue, K. Yasuda, K. Suzuki, H. Takeuchi, and T. Nishizaki Angiopoietin 2 expression in invasive ductal carcinoma of the breast: its relationship to the VEGF expression and microvessel density Breast Cancer Res Treat 98 2006 261 266
37. I.B. Lobov, P.C. Brooks, and R.A. Lang Angiopoietin-2 displays VEGF-dependent modulation of capillary structure and endothelial cell survival in vivo Proc Natl Acad Sci U S A 99 2002 11205 11210
38. H.S. Lim, G.Y. Lip, and A.D. Blann Angiopoietin-1 and angiopoietin-2 in diabetes mellitus: relationship to VEGF, glycaemic control, endothelial damage/dysfunction and atherosclerosis Atherosclerosis 180 2005 113 118
39. D.R. Cox Regression models and life tables J. R. Stat. Soc. Ser. B 34 1972 187 220
40. N. Mantel Evaluation of survival data and two new rank order statistics arising in its consideration Cancer Chemother Rep 50 1966 163 170